El resultado intermedio como problema clínico y de salud pública. A propósito de la mortalidad por cerivastatina

The Impact of New Drug Introduction on Drug Expenditure in Primary Health Care in Catalunya, Spain

“…Mortality due to rhabdomyolysis originating from its use should stimulate a review of the whole process of approval, commercial availability, and use of new medications. 8…”